20%-nonrespondersa | 20%-respondersa | P-value | |
---|---|---|---|
Mean ± SE | Mean ± SE | ||
Average of placebo run-in and randomization (Visits 0, 1, 2) | n = 212 | n = 81 | |
EQ-5D at baseline | 0.693 ± 0.005 | 0.698 ± 0.006 | NS |
Week 2 (Visit 3) | n = 207 | n = 79 | |
Change from baseline, EQ-5D | 0.003 ± 0.003 | 0.019 ± 0.006 | 0.02 |
Change from baseline, ES | 0.052 ± 0.054 | 0.300 ± 0.088 | |
Week 6 (Visit 4) | n = 206 | n = 79 | |
Change from baseline, EQ-5D | −0.002 ± 0.003 | 0.030 ± 0.005 | <0.001 |
Change from baseline, ES | −0.036 ± 0.051 | 0.483 ± 0.086 | |
Week 10 (Visit 5) | n = 202 | n = 76 | |
Change from baseline, EQ-5D | −0.008 ± 0.004 | 0.027 ± 0.006 | <0.001 |
Change from baseline, ES | −0.128 ± 0.055 | 0.435 ± 0.094 | |
Week 14 (Visit 6) | n = 201 | n = 78 | |
Change from baseline, EQ-5D | −0.016 ± 0.004 | 0.032 ± 0.007 | <0.001 |
Change from baseline, ES | −0.248 ± 0.062 | 0.515 ± 0.115 | |
Week 16 (Visit 7) | n = 207 | n = 79 | |
Change from baseline, EQ-5D | −0.026 ± 0.004 | −0.007 ± 0.007 | 0.01 |
Change from baseline, ES | −0.418 ± 0.065 | −0.104 ± 0.110 | |
Week 18 (Visit 8) | n = 203 | n = 79 | |
Change from baseline, EQ-5D | −0.026 ± 0.004 | −0.016 ± 0.007 | NS |
Change from baseline, ES | −0.420 ± 0.061 | −0.263 ± 0.108 |